Immunotherapy of Gastric Ulcer Disease, Associated with Heliœbacter pylori Using Recombinant IL-2
Aim. To determine the clinical, morphological and microbiological efficacy of treatment of gastric ulcer associated with Helicobacter pylori, using recombinant interleukin-2 "Roncoleukin" without antibiotics. Materials and methods. 108 patients suffering from HP-associated gastric ulcer disease were randomly divided into two groups. The I group of patients was cured with standard three or four component methods of therapy included proton pomp inhibitors and two antibiotics (usually Klaritromycin and Amoxicillin). Patients of the second group were treated with the same therapy, but instead of antibiotics they received 0,1 mg rIL-2 - Roncoleukin into four - six points submucously using gastroscope techniques and 0,4 mg was dissolved in 400 ml 0,9% NaCl and infused intravenously. This procedure was performed three times with the interval of 72 hours. Results. One month after the end of treatment it was found that in the group treated with rIL-2 the HP eradication achieved in 95,4% in comparison to 81,5% in control patients. In Roncoleukin treated group ulcer epithelization period was 10,79±0,46 days and in traditionally treated group - 35,23±1,58 days. In third month of monitoring in gastric mucosae bioptates of basic group patients in 93,5% there were no morphological inflammatory signs and in 81,4% of patients intestinal metaplasia disappiered. Conclusion. The proposed method of complex treatment of gastric ulcer associated with Helicobacter pylori is clinically and pathogenetically justified.